Literature DB >> 20103585

SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells.

Jason A Funk1, Sina Odejinmi, Rick G Schnellmann.   

Abstract

Mitochondrial biogenesis occurs under basal conditions and is an adaptive response initiated by cells to maintain energetic demands and metabolic homeostasis after injuries targeting mitochondrial function. Identifying pharmacological agents that stimulate mitochondrial biogenesis is a critical step in the development of new therapeutics for the treatment of these injuries and to test the hypothesis that these agents will expedite recovery of cell and organ function after acute organ injuries. In this study, we examined the effects of N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide (SRT1720) on mitochondrial biogenesis and function in primary cultures of renal proximal tubule cells (RPTCs). We also tested the ability of this compound to restore mitochondrial functions after oxidant-induced RPTC injury. SRT1720 (3-10 microM) induced mitochondrial biogenesis in RPTCs within 24 h as determined by elevations in mitochondrial DNA copy number, increased expression of the mitochondrial proteins NADH dehydrogenase 1beta subcomplex subunit 8 (NDUFB8) and ATP synthase beta, and elevated mitochondrial respiration rates and ATP levels. Induction of mitochondrial biogenesis depended on mammalian sirtuin 1 (SIRT1) deacetylase activity, correlated with deacetylated nuclear peroxisome proliferator-activated receptor coactivator (PGC)-1alpha, and occurred in the absence of AMP-dependent kinase (AMPK) activation. Finally, SRT1720 treatment accelerated recovery of mitochondrial functions after acute oxidant injury. This study demonstrates that SRT1720 can induce mitochondrial biogenesis through SIRT1 activity and deacetylated PGC-1alpha, but not AMPK, in RPTCs within 24 h after oxidant injury. The results support further study of mitochondrial biogenesis as a repair process and a pharmacological target in acute organ injuries and disorders plagued by mitochondrial impairment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20103585      PMCID: PMC2872958          DOI: 10.1124/jpet.109.161992

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  44 in total

1.  The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases.

Authors:  J Landry; A Sutton; S T Tafrov; R C Heller; J Stebbins; L Pillus; R Sternglanz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

2.  Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation.

Authors:  Jérôme N Feige; Marie Lagouge; Carles Canto; Axelle Strehle; Sander M Houten; Jill C Milne; Philip D Lambert; Chikage Mataki; Peter J Elliott; Johan Auwerx
Journal:  Cell Metab       Date:  2008-11       Impact factor: 27.287

3.  Mitochondrial dysfunction during hypoxia/reoxygenation and its correction by anaerobic metabolism of citric acid cycle intermediates.

Authors:  J M Weinberg; M A Venkatachalam; N F Roeser; I Nissim
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 4.  Thyroid hormone action in mitochondria.

Authors:  C Wrutniak-Cabello; F Casas; G Cabello
Journal:  J Mol Endocrinol       Date:  2001-02       Impact factor: 5.098

5.  The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1{alpha}.

Authors:  Agnès Coste; Jean-Francois Louet; Marie Lagouge; Carles Lerin; Maria Cristina Antal; Hamid Meziane; Kristina Schoonjans; Pere Puigserver; Bert W O'Malley; Johan Auwerx
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-28       Impact factor: 11.205

6.  Resveratrol induces mitochondrial biogenesis in endothelial cells.

Authors:  Anna Csiszar; Nazar Labinskyy; John T Pinto; Praveen Ballabh; Hanrui Zhang; Gyorgy Losonczy; Kevin Pearson; Rafael de Cabo; Pal Pacher; Cuihua Zhang; Zoltan Ungvari
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-08       Impact factor: 4.733

7.  AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity.

Authors:  Carles Cantó; Zachary Gerhart-Hines; Jerome N Feige; Marie Lagouge; Lilia Noriega; Jill C Milne; Peter J Elliott; Pere Puigserver; Johan Auwerx
Journal:  Nature       Date:  2009-04-23       Impact factor: 49.962

8.  Oxidants and Ca+2 induce PGC-1alpha degradation through calpain.

Authors:  Kyle A Rasbach; Peter T Green; Rick G Schnellmann
Journal:  Arch Biochem Biophys       Date:  2008-08-08       Impact factor: 4.013

9.  Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo.

Authors:  Jesse J Smith; Renée Deehan Kenney; David J Gagne; Brian P Frushour; William Ladd; Heidi L Galonek; Kristine Israelian; Jeffrey Song; Giedre Razvadauskaite; Amy V Lynch; David P Carney; Robin J Johnson; Siva Lavu; Andre Iffland; Peter J Elliott; Philip D Lambert; Keith O Elliston; Michael R Jirousek; Jill C Milne; Olivier Boss
Journal:  BMC Syst Biol       Date:  2009-03-10

10.  SirT1 regulates energy metabolism and response to caloric restriction in mice.

Authors:  Gino Boily; Erin L Seifert; Lisa Bevilacqua; Xiao Hong He; Guillaume Sabourin; Carmen Estey; Cynthia Moffat; Sean Crawford; Sarah Saliba; Karen Jardine; Jian Xuan; Meredith Evans; Mary-Ellen Harper; Michael W McBurney
Journal:  PLoS One       Date:  2008-03-12       Impact factor: 3.240

View more
  78 in total

1.  Persistent disruption of mitochondrial homeostasis after acute kidney injury.

Authors:  Jason A Funk; Rick G Schnellmann
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-07

Review 2.  Sirtuin activators and inhibitors.

Authors:  José M Villalba; Francisco J Alcaín
Journal:  Biofactors       Date:  2012-06-25       Impact factor: 6.113

3.  Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells.

Authors:  Dharminder Chauhan; Madhavi Bandi; Ajita V Singh; Arghya Ray; Noopur Raje; Paul Richardson; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2011-09-26       Impact factor: 6.998

Review 4.  Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.

Authors:  Ralph A DeFronzo; W Brian Reeves; Alaa S Awad
Journal:  Nat Rev Nephrol       Date:  2021-02-05       Impact factor: 28.314

Review 5.  Pharmacological targets in the renal peritubular microenvironment: implications for therapy for sepsis-induced acute kidney injury.

Authors:  Philip R Mayeux; Lee Ann MacMillan-Crow
Journal:  Pharmacol Ther       Date:  2012-01-16       Impact factor: 12.310

6.  Mitochondrial Homeostasis in Acute Organ Failure.

Authors:  L Jay Stallons; Jason A Funk; Rick G Schnellmann
Journal:  Curr Pathobiol Rep       Date:  2013-09

7.  Arginase-2 mediates renal ischemia-reperfusion injury.

Authors:  Wesley M Raup-Konsavage; Ting Gao; Timothy K Cooper; Sidney M Morris; W Brian Reeves; Alaa S Awad
Journal:  Am J Physiol Renal Physiol       Date:  2017-05-17

8.  cGMP-selective phosphodiesterase inhibitors stimulate mitochondrial biogenesis and promote recovery from acute kidney injury.

Authors:  Ryan M Whitaker; Lauren P Wills; L Jay Stallons; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2013-09-16       Impact factor: 4.030

9.  Accelerated recovery of renal mitochondrial and tubule homeostasis with SIRT1/PGC-1α activation following ischemia-reperfusion injury.

Authors:  Jason A Funk; Rick G Schnellmann
Journal:  Toxicol Appl Pharmacol       Date:  2013-10-03       Impact factor: 4.219

10.  SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis.

Authors:  Petra Simic; Eric O Williams; Eric L Bell; Jing Jing Gong; Michael Bonkowski; Leonard Guarente
Journal:  Cell Rep       Date:  2013-04-11       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.